Intratumoral Heterogeneity and Immune Response Indicators to Predict Overall Survival in a Retrospective Study of HER2-Borderline (IHC 2+) Breast Cancer Patients.
CD8
HER2
breast cancer
digital pathology
immune response
intratumoral heterogeneity
tumor microenvironment
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
09
2021
accepted:
22
10
2021
entrez:
3
12
2021
pubmed:
4
12
2021
medline:
4
12
2021
Statut:
epublish
Résumé
Breast cancer (BC) categorized as human epidermal growth factor receptor 2 (HER2) borderline [2+ by immunohistochemistry (IHC 2+)] presents challenges for the testing, frequently obscured by intratumoral heterogeneity (ITH). This leads to difficulties in therapy decisions. We aimed to establish prognostic models of overall survival (OS) of these patients, which take into account spatial aspects of ITH and tumor microenvironment by using hexagonal tiling analytics of digital image analysis (DIA). In particular, we assessed the prognostic value of Immunogradient indicators at the tumor-stroma interface zone (IZ) as a feature of antitumor immune response. Surgical excision samples stained for estrogen receptor (ER), progesterone receptor (PR), Ki67, HER2, and CD8 from 275 patients with HER2 IHC 2+ invasive ductal BC were used in the study. DIA outputs were subsampled by HexT for ITH quantification and tumor microenvironment extraction for Immunogradient indicators. Multiple Cox regression revealed HER2 membrane completeness (HER2 MC) (
Identifiants
pubmed: 34858854
doi: 10.3389/fonc.2021.774088
pmc: PMC8631965
doi:
Types de publication
Journal Article
Langues
eng
Pagination
774088Informations de copyright
Copyright © 2021 Radziuviene, Rasmusson, Augulis, Grineviciute, Zilenaite, Laurinaviciene, Ostapenko and Laurinavicius.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Immunother Cancer. 2016 Oct 18;4:59
pubmed: 27777769
Breast Cancer Res. 2015 Sep 22;17(1):131
pubmed: 26395345
Lancet Oncol. 2014 Feb;15(2):e58-68
pubmed: 24480556
Comput Biol Med. 2015 Feb;57:123-9
pubmed: 25553357
Lancet Oncol. 2010 Mar;11(3):266-74
pubmed: 20079691
Cancer Treat Rev. 2016 May;46:20-6
pubmed: 27057657
Ann Oncol. 2013 Nov;24(11):2715-24
pubmed: 23908178
Cancer Invest. 2010 Nov;28(9):963-8
pubmed: 20690807
Endocr Rev. 2008 Apr;29(2):217-33
pubmed: 18216219
Cancer Treat Rev. 2017 Jun;57:8-15
pubmed: 28525810
Histopathology. 2010 Jul;57(1):27-38
pubmed: 20584089
Cancer Treat Rev. 2020 Aug;88:102064
pubmed: 32622272
Breast Cancer Res Treat. 2012 Feb;132(1):41-9
pubmed: 21512768
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Lab Invest. 2012 Sep;92(9):1342-57
pubmed: 22801299
Nature. 2006 Apr 20;440(7087):1045-9
pubmed: 16625196
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
Breast Cancer Res Treat. 2020 Aug;183(1):49-59
pubmed: 32577938
J Clin Oncol. 2015 May 20;33(15):1680-7
pubmed: 25897160
Front Genet. 2020 Oct 23;11:578345
pubmed: 33193699
Virchows Arch. 2015 Oct 19;:
pubmed: 26481244
Histopathology. 2015 Dec;67(6):880-7
pubmed: 25913507
Breast Care (Basel). 2020 Dec;15(6):586-593
pubmed: 33447232
Am J Clin Pathol. 2017 Jan 1;147(1):89-95
pubmed: 28110280
Cancers (Basel). 2020 Jun 15;12(6):
pubmed: 32549380
Biomed Res Int. 2017;2017:2321916
pubmed: 28752092
Mod Pathol. 2017 Feb;30(2):227-235
pubmed: 27739440
Lancet. 2020 Dec 5;396(10265):1817-1828
pubmed: 33278935
Am J Pathol. 2021 Oct;191(10):1724-1731
pubmed: 33895120
J Clin Pathol. 2011 Dec;64(12):1112-6
pubmed: 22011446
Int J Mol Sci. 2021 Jan 10;22(2):
pubmed: 33435254
Ann Oncol. 2014 Aug;25(8):1544-50
pubmed: 24608200
Oncology. 2001;61 Suppl 2:1-13
pubmed: 11694782
J Clin Oncol. 2010 Jan 1;28(1):105-13
pubmed: 19917869
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
J Clin Oncol. 2013 Mar 1;31(7):860-7
pubmed: 23341518
Cancer Res. 2012 Sep 1;72(17):4417-28
pubmed: 22773664
Ann Oncol. 2013 Jan;24(1):47-53
pubmed: 22847811
Ann Oncol. 2018 Jan 1;29(1):170-177
pubmed: 29045543
Oncologist. 2014 Nov;19(11):1118-26
pubmed: 25323485
Eur J Cancer. 2018 Jan;89:9-18
pubmed: 29223481
Ann Oncol. 2014 Aug;25(8):1536-43
pubmed: 24915873
Cells. 2021 Apr 02;10(4):
pubmed: 33918173
J Clin Invest. 2010 Feb;120(2):636-44
pubmed: 20101094
Cancers (Basel). 2021 Mar 01;13(5):
pubmed: 33804398
J Clin Med. 2019 Jan 24;8(2):
pubmed: 30682851
J Immunother Cancer. 2017 Apr 18;5:39
pubmed: 28428887
J Natl Cancer Inst. 2018 Feb 1;110(2):
pubmed: 28859291
J Clin Oncol. 2018 Jul 10;36(20):2105-2122
pubmed: 29846122
Am J Clin Pathol. 2019 Jun 5;152(1):17-26
pubmed: 30958889
Am J Pathol. 2020 Jun;190(6):1309-1322
pubmed: 32194048
Lancet Oncol. 2020 Jan;21(1):44-59
pubmed: 31786121
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Mod Pathol. 2012 Jul;25(7):938-48
pubmed: 22388760
J Immunother Cancer. 2019 Mar 29;7(1):90
pubmed: 30922362
Br J Cancer. 2021 May;124(11):1836-1842
pubmed: 33762723
MD Comput. 1997 Jul-Aug;14(4):306-17
pubmed: 9230594
PLoS One. 2012;7(12):e51862
pubmed: 23251644
PLoS One. 2016 Apr 13;11(4):e0152500
pubmed: 27073890
J Clin Oncol. 2020 Jun 10;38(17):1951-1962
pubmed: 32330069
Neoplasia. 2014 Oct 23;16(10):861-7
pubmed: 25379022
J Natl Cancer Inst. 2019 Aug 1;111(8):867-871
pubmed: 30888406
Am J Clin Pathol. 2015 Aug;144(2):278-88
pubmed: 26185313
PLoS One. 2017 May 11;12(5):e0177331
pubmed: 28493933
Cancer Immunol Res. 2014 Apr;2(4):361-70
pubmed: 24764583
Int J Mol Sci. 2019 Mar 05;20(5):
pubmed: 30841523
Front Oncol. 2020 Jun 16;10:950
pubmed: 32612954
Semin Cancer Biol. 2021 Jul;72:102-113
pubmed: 32259641
J Clin Oncol. 2015 Mar 1;33(7):701-8
pubmed: 25605861
BMC Cancer. 2019 Mar 4;19(1):200
pubmed: 30832597
Hum Pathol. 2020 Apr;98:10-21
pubmed: 32027910
IEEE J Biomed Health Inform. 2021 Feb;25(2):381-392
pubmed: 32750943
J Clin Oncol. 2020 Jun 10;38(17):1887-1896
pubmed: 32058843
Breast. 2016 Oct;29:241-50
pubmed: 27481651
Diagn Pathol. 2011 Sep 23;6:87
pubmed: 21943197
J Clin Oncol. 2010 Jan 1;28(1):92-8
pubmed: 19933921
Virchows Arch. 2016 Apr;468(4):493-502
pubmed: 26818835
Mod Pathol. 2014 Jan;27(1):4-18
pubmed: 23807776
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
Semin Cancer Biol. 2021 Jul;72:123-135
pubmed: 32112814
Breast Cancer Res. 2019 Aug 7;21(1):90
pubmed: 31391067
Clin Cancer Res. 2015 Mar 15;21(6):1258-66
pubmed: 25770293
Cancer Cell. 2010 Aug 9;18(2):160-70
pubmed: 20708157
Appl Immunohistochem Mol Morphol. 2008 Mar;16(2):185-90
pubmed: 18227722
Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7142-7
pubmed: 21482773
PLoS Med. 2016 Feb 16;13(2):e1001961
pubmed: 26881778
J R Soc Interface. 2015 Feb 6;12(103):
pubmed: 25505134
JAMA Oncol. 2016 Jan;2(1):56-64
pubmed: 26469139
Front Immunol. 2017 Nov 28;8:1679
pubmed: 29234329
Mod Pathol. 2015 Dec;28(12):1621
pubmed: 26621491
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
J Clin Oncol. 2011 May 20;29(15):1949-55
pubmed: 21483002
Future Oncol. 2016 Jun;12(11):1413-28
pubmed: 27007660
Cancer Treat Rev. 2016 May;46:9-19
pubmed: 27055087
Breast Cancer Res Treat. 2017 Nov;166(2):447-457
pubmed: 28799059
Breast Care (Basel). 2013 Aug;8(4):256-62
pubmed: 24415978
Virchows Arch. 2016 Feb;468(2):191-8
pubmed: 26493985
PLoS One. 2020 Nov 12;15(11):e0241775
pubmed: 33180796
Breast Cancer Res. 2016 Dec 3;18(1):121
pubmed: 27912781
JAMA Oncol. 2015 Jul;1(4):448-54
pubmed: 26181252
Histopathology. 2011 Jun;58(7):1107-16
pubmed: 21707712
Pathol Res Pract. 2018 Dec;214(12):2087-2092
pubmed: 30377025
Clin Cancer Res. 2007 Apr 1;13(7):1950-4
pubmed: 17404074
Breast Cancer Res Treat. 2019 May;175(1):51-57
pubmed: 30712197
Lancet Oncol. 2009 Mar;10(3):267-77
pubmed: 19261255
Oncogene. 2003 Oct 20;22(47):7316-39
pubmed: 14576841
Breast Cancer Res. 2012 Mar 15;14(2):R48
pubmed: 22420471
Pathol Res Pract. 2019 Feb;215(2):251-255
pubmed: 30420102
Cell Rep. 2014 Feb 13;6(3):514-27
pubmed: 24462293
J Clin Oncol. 1999 Sep;17(9):2639-48
pubmed: 10561337
Breast Cancer Res. 2012 Mar 14;14(2):R46
pubmed: 22417870
PLoS One. 2014 Apr 17;9(4):e95475
pubmed: 24743335
Breast Cancer Res Treat. 2015 Jul;152(2):367-75
pubmed: 26109345